Please assess the completion status of the following clinical trial:

Trial Title: Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female ≥ 18 years, ≤70 years.~* Has measurable metastatic MBC, with at least 1 measurable lesion per RECIST criteria.~* Fail first-line or above anti-tumor treatment~* Evaluation is stable disease with a trend of progression.~* Minimum life expectancy 16 weeks~* Histological confirmation of breast cancer on primary tumour at diagnosis/on biopsy of metastasis~* ECOG Performance Status (PS) 0-2 with no deterioration over previous 2 weeks~* Normal organ function.~* Has signed a Patient Informed Consent Form~Exclusion Criteria:~* Hypersensitivity to moxifloxacin or other quinolones.~* Tendon damage,peripheral neuropathy,myasthenia gravis.~* Rapidly progressive visceral disease not suitable for further therapy.~* Evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis B, hepatitis C and HIV~* With the exception of alopecia, any unresolved toxicities from previous therapy greater than CTCAE grade 1 before study treatment~* Evidence of dementia, altered mental status or any psychiatric condition that would prohibit understanding or rendering of informed consent~* Inability or unwillingness to comply with study procedures, including inability to take regular oral medication~* Researchers consider it is not suitable for participation.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- routine therapy plus moxifloxacin (Type: EXPERIMENTAL): Routine therapy (chemotherapy, endocrine therapy or target therapy) is according to physician's choice.

Based on this trial design, predict the completion outcome and termination type (if applicable).